Objectives: Creation of functional, durable vasculature remains an important goal within the field of regenerative medicine. Engineered biological vasculature has the potential to restore or improve human tissue function. We hypothesized that the pleotropic effects of insulin-like growth factor 1 (IGF1) would enhance the engineering of capillary-like vasculature. Results: IGF1 supplementation significantly enhanced de novo vasculogenesis both in vitro and in vivo. Effects were long-term as they lasted the duration of the study period, and included network density, vessel length, and diameter. Bifurcation density was not affected. However, the highest concentrations of IGF1 tested were either ineffective or even deleterious. Sustained IGF1 delivery was required in vivo as the inclusion of recombinant IGF1 protein had minimal impact.
vascular networks that rapidly anastomose with host vessels and become functional soon after implantation.
Studies using clinically relevant progenitor sources for pericytes and endothelial cells (ECs) show that they can generate functional microvascular networks. [2] [3] [4] [5] These networks, however, are typically immature and may rapidly regress. Vascular development and remodelling is dependent on several growth factors, the best known of which are
Vascular Endothelial Growth Factor (VEGF) A, and Fibroblast Growth
Factor (FGF) 2. [6] [7] [8] [9] Improved engineered vasculature would allow ischemic and traumatic tissue defects to be treated more effectively and efficiently. [9] [10] [11] [12] [13] The insulin super-family is composed of 10 members in mammals, insulin, 2 insulin-like growth factors, 3 relaxin proteins, and 4 insulinlike peptides. Sequence conservation is minimal; the major commonality is structural, as they all have 3 characteristic disulfide bonds.
They also have diverse physiological roles. Among its many functions, insulin-like growth factor 1 (IGF1) is recognized as an angiogenic factor, along with specific members of the VEGF, FGF, Bone Morphogenetic Protein (BMP), Tissue Growth Factor (TGF), and Hepatocyte Growth Factor (HGF) families. [14] [15] [16] [17] However, the normal regulatory role of IGF1 in promoting angiogenesis is not particularly well understood as most research has focused upon its possible pathogenic participation in promoting aberrant vascularization during retinopathy and tumour growth. In addition, many reports are highly contradictory, perhaps reflecting the importance of the precise context of the studies and the pleiotropic nature of the growth factor and its receptor. 18, 19 IGF1 is an effective FDA-approved therapy for children with short stature as it has a beneficial effect upon the entire musculoskeletal system. In addition to its anabolic properties, IGF1 enhances tissue repair by promoting angiogenesis and attenuating inflammation, necrosis, and apoptosis. Systemic IGF1 is largely synthesized by the liver. Its expression is controlled by Growth Hormone (GH) and mediates much of its growth-promoting activity. IGF1 is a small peptide and is rapidly cleared by the kidneys (t1/2 = 15 minute) if not in a binary complex with a member of the IGF1-binding protein family (IGFBP) or ternary complex with an additional acid labile subunit. 20 However, being complexed appears to most often reduce the bio-availability of systemic IGF1 as it cannot bind receptor. In addition, ternary complexes are unable to transit capillary walls. Although total IGF1 levels are typically in the 175-260 ng/mL in young adults, 21 only 0.2-0.6 ng/mL in serum and 3.6-10 ng/mL in interstitial fluid is free and bioavailable. Because IGF1 binding proteins are in vast excess to their ligand, 21 simply increasing total levels of system IGF1 has minimal impact on free levels.
An engineered version of human IGF1, LR3IGF-I, was generated by inserting the first 11 amino acids of methionyl porcine growth hormone followed by the dipeptide VN and mutating the third codon encoding the mature human IGF1 peptide (E3R); this created a protein that can no longer be sequestered by IGFBPs yet can still bind and activate the IGF1 receptor. 22 However, like native unbound IGF1, LR3IGF-I is also rapidly cleared. IGF1 is also synthesized locally by most tissues 
| MATERIALS AND METHODS

| Study design
| Vascular cell preparations
Bone marrow samples were obtained from patients undergoing hip replacement surgery with the approval of the Institutional Review Board of Massachusetts General Hospital. hMSC cultures were established essentially as previously described. 23 
| Formation of vascular constructs
The standard protocol for vascularization (control group) was based on previous studies. 2, 28 Our prior work indicated a ratio of 2:1 of HUVECS and MSCs was optimal for inducing and maintaining vascular structures in a hydrogel. 3 Here, preliminary experiments were performed to confirm conditions for vasculogenesis with our cell preparations and materials, and to verify that inclusion of unmodi- 
| Quantification of IGF1 release in vitro
IGF1 synthesis levels by HEK-IGF1 cells was measured using the 
| Immunodeficient mouse model
The subcutaneous injection procedure for producing vascularized hydrogel plugs in immunodeficient mice was used to evaluate the effect of IGF1 in vivo, 28 with ice-cold collagen-fibronectin plugs containing co-cultures that gelled when warmed to body temperature. and high concentrations of HEK-IGF1 and rIGF1 were studied; cell rations and recombinant protein concentrations were identical to those used in the in vitro studies. At least three technical replicates of each of the four conditions for both HEK-IGF1 and rIGF1 were implanted.
The cell compositions of the HEK-IGF1 were identical to those used for the in vitro studies.
Ten severe immunodeficient mice (NOD.CB17, Jackson
Laboratory, Bar Harbor, ME) were implanted, four samples/mouse.
Animals were anesthetized with a Ketamine/Xylazine solution (c = 1 mg/30 g mouse) for pain relief for the implant injections.
Collagen-fibronectin gels were created on ice as described above prior to subcutaneous dorsal injection using a 1 mL syringe fitted with a 26 gauge needle. Each mouse received one plug of each of the four conditions; the positions were rotated in each mouse to different quadrants (crossover design). At 2 weeks, the plugs were explanted from sacrificed mice and analyzed via confocal microscopy imaging and histology.
| Imaging measurements using light microscopy
A Nikon A1 confocal microscope for detection and measurements of the vascularized collagen plugs with a 20× objective was used for imaging vascular networks. Representative regions mid-depth for each sample were imaged. Analysis of images was performed in ImageJ using the Vascular Network Toolkit Plug-in. 30 The red (HUVEC) channel of each image was isolated and the thresholding function used to generate a 2-bit skeletal vascular map from which the network values were quantified. Node analysis was performed, and distance measurements between nodes and density per unit area obtained. Thickness function was used to determine average vessel radius; this value was doubled and data presented as diameter. Vessel density was determined by determining the fractional area incorporated into vessels in the skeletonized images.
| Histological preparation and analysis
For histological analysis, the collagen-fibronectin plugs were excised from mice and fixed in 4% paraformaldehyde solution overnight at 4°C. Samples were dehydrated and embedded in paraffin by standard conditions. Transverse sections 10 μm thick were cut and processed for immunohistochemistry using primary antibody 
| Statistical analysis
To compare four setups at several time points, a non-parametric repeated measurement ANOVA was used for group comparison.
31
The Mann-Whitney-U Test was used for comparison of two independent setups per time point. 31 Group effect, time effect, and the interactions between group and time were investigated. A P < .05 was considered to be significant. Due to the exploratory study design and the weakness of post hoc power analysis, all calculated P values were considered in a non-confirmatory way. Missing data was accounted for using the last observation carried forward (LOCF) 
| RESULTS
| HEK-IGF1 significantly enhanced in vitro vascular network formation
In order to evaluate the impact of IGF1 on vasculogenesis, HEK- In contrast, high levels of HEK-IGF1 produced inferior networks that were largely indistinguishable or worse than control cultures. These differences were maintained throughout the entire experimental time course.
Co-cultures with low or medium levels of HEK-IGF1 had positive effects upon vessel length relative to controls throughout the experiment ( Figure 3A ). High levels of HEK-IGF1 produced networks that were initially similar to both control and medium levels. After day 3, networks became dramatically worse than all other conditions. Vessel lengths were consistently shorter at the highest HEK-IGF1 levels for the remainder of the study period.
Control co-cultures displayed the greatest average vessel diameter at day 3, after which it gradually declined ( Figure 3B ). All The number of vessel bifurcations occurring under each condition was also determined, but differences were not statistically significant (data not shown).
| Quantification of IGF1 release by HEK-IGF1
We wanted to determine if medium supplemented with rIGF1 protein could substitute for that produced by HEK-IGF1. Synthesis levels were assessed using ELISA to measure IGF1 in the medium of co-cultures containing HEK-293, or low, medium, or high levels of HEK-IGF1. 
| rIGF1 protein stabilizes in vitro vascular networks
Co-cultures were prepared with rIGF1 protein replacing HEK-IGF1.
Again, three levels of IGF1 supplementation were compared to unsupplemented control cultures. For low and medium cultures, rIGF1 levels were chosen to match those measured in the corresponding HEK-IGF1 setups. Because the highest HEK-IGF1 levels were clearly toxic, a lower concentration of recombinant protein was used in the high-level cultures. Co-cultures were followed until compaction of the hydrogel made imaging difficult (36 days). Supplementation with rIGF1 again dramatically impacted vasculogenesis, with visible differences readily detectable throughout the culture period (Figure 4 ).
Although the resulting networks were similar to those prior, rIGF1
supplementation did not precisely mirror that with HEK-IGF1. For high rIGF1 co-cultures, the reduced growth factor level was still deleterious, and like unsupplemented co-cultures, had few surviving ECs.
Both low and medium rIGF1 levels promoted network survival to a similar degree. However, the resulting networks were notably less dense with shorter branches ( Figure 5A ). In addition, vessel diameters were greatly reduced ( Figure 5B ).
| Assessment IGF1 treatment on in vivo vascular networks
To assess potential in vivo functionality of IGF1-enhanced vascular networks, co-cultures containing collagen-fibronectin plugs were produced vessels that were uniform in appearance, they still maintained a degree of tortuous (immature) character. In contrast, vessels in medium HEK-IGF1 samples appeared noticeably more linear.
Explants containing rIGF1 supplementation produced networks at all levels. No toxicity was seen at high levels of rIGF1. However, supplementation with rIGF1 caused a small but significant increase in the low dosage only; the highest levels were somewhat detrimental. Average vessel diameters were unchanged at all dosages ( Figure 7B ). Paraffin sections from embedded samples were probed with a human-specific antibody against the endothelial marker CD31. Numerous HUVEC-derived capillaries were present in both HEK-IGF1 and rIGF1 supplemented implants. The vessels were filled with blood cells, providing evidence of the patency of the vascular lumen and anastomosis of the network ( Figure 6C ). F I G U R E 7 HEK-IGF1 but not rIGF1 supplementation promotes extensive vascular networks in vivo. Average vessel lengths and diameters were calculated from images of the explanted plugs and plotted for HEK-IGF1 (A) and rIGF1 (B). NS = not significant application of the growth factor is often not efficacious for treating localized ailments. IGF1 bio-availability is tightly regulated by both its binding proteins and turnover; specific local applications may need to be developed in order to take advantage of its properties.
| DISCUSSION
IGF1 can potentially mediate angiogenesis through several mechanisms, as both ECs and mural cells express significant levels of IGF1 receptor. 41, 42 IGF1 robustly promotes proliferation of vascular smooth muscle cells. 43 Reports of the effect upon EC proliferation vary, and may depend upon the vascular bed being studied. 14, 15, 35, 43 IGF1 stimulates migration of both smooth muscle and ECs. 37, 38 It promotes EC migration through phosphatidylinositol 3-kinase (PI3K) activation. 44 Importantly, at moderate levels, it is also a major survival factor for a broad range of cell types, and is able to prevent cell death and apoptosis during normal development, stress, repair, and disease. 45 The role in modulating inflammatory response is more nuanced, as many studies document inhibition by IGF1 signalling 46 19, 58, 59 Both cell types, however, are fully capable of responding to IGF1 signalling as they both abundantly express the receptor. 41, 42 Furthermore, some of the effects documented in this study may secondary, as IGF1 stimulation can induce synthesis of will be of significant interest.
